ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer

BACKGROUND: Immunotherapy with checkpoint inhibitors (CPI) targeting PD-1 or CTLA-4 has emerged as an important treatment modality for several cancer forms. In hormone receptor positive breast cancer (HR + BC), this therapeutic approach is largely unexplored. We have started a clinical trial, ICON (...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Transl Med
Autori principali: Kyte, J. A., Andresen, N. K., Russnes, H. G., Fretland, S. Ø., Falk, R. S., Lingjærde, O. C., Naume, B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Protocol
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7333428/
https://ncbi.nlm.nih.gov/pubmed/32620163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02421-w
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi